Irish Horizons: Sitting Down With BMS’ Karen Costello

How have previous geographic roles helped you prepare for your new role in Ireland?
 

I’m approaching my 24^th anniversary with Bristol Myers Squibb (BMS). The majority of my career has been based in the UK, but I’ve also worked in various global markets and roles.

I was thrilled when I had the opportunity to work in the US. The scale of operations in the US, coupled with the diverse healthcare system, presented a unique dynamic. The pace of innovation in the US, both in technology and data availability, was remarkable. The emphasis on faster patient access and partnerships with renowned institutions was also incredible. This broader perspective will be invaluable as I now take on a role in Ireland.

As General Manager, I’m focused on developing a robust strategy, leveraging the skilled and passionate team here, and ensuring Ireland continues to grow as a critical hub for BMS. My US experience has underscored the importance of developing achievable plans - whilst still aiming high - and fostering external collaboration to help enhance medicine access in Ireland. Key for me will be taking a people-first approach; ensuring the right skills are in the right positions and creating a supportive culture. Leading with a clear vision, focusing on projects that will have the greatest impact, and embracing opportunities to innovate and grow, are equally essential. 

What will be your focus in Ireland?
 

My time in the US gave me a closer view of BMS' enterprise-wide operations, which I’m keen to integrate into our work in Ireland. Leveraging the connections and insights gained in New Jersey, I aim to unlock new opportunities while emphasizing the vital role our Irish team plays. Ultimately, my focus will remain consistent: helping to ensure Irish patients gain timely access to the medicines they need. This is a deeply personal mission for me and drives my commitment to excellence in our work.

How important is Ireland to BMS?
 

Ireland has a stellar reputation as a global biopharma hub, backed by world-class facilities, a robust regulatory environment, and strong industry-academia collaboration. These factors create a solid foundation for innovation. At BMS, our vision is to make medicines more accessible to patients worldwide, and Ireland plays a pivotal role in that mission.

Our operations in Ireland include a biologics facility in Cruiserath, Dublin and external manufacturing divisions in Blanchardstown, Dublin and Shannon, County Clare. These sites exemplify our commitment to innovation and patient care. Last year, we announced a $400 million investment in a sterile drug product facility at our Cruiserath campus, slated to launch in 2026. This will not only enhance our manufacturing capabilities, but will also create around 350 jobs, reinforcing Ireland’s standing as a biopharma leader.  

What do you enjoy doing in your spare time?
 

I’m very sociable and love spending time with family and friends. Since returning to Ireland, it’s been wonderful to reconnect and be present with loved ones. I enjoy the theatre, exploring cuisines, and planning European trips. Italy is high on my list, but I’m also eager to explore more of Ireland. Rediscovering the evolving beauty of my home country feels like a meaningful way to connect with my roots and appreciate the country more. Dublin’s vibrant restaurant scene is especially exciting. Staying active is also important, though I’ve yet to reestablish my gym routine after months of travel. I’m also considering taking up golf, which will hopefully provide a new outlet for relaxation.

How do these interests complement your professional work?
 

They provide balance and perspective. Whether travelling, exploring new cuisines, or engaging in physical activities, these interests help me recharge and maintain mental clarity. This balance is crucial for bringing my best self to work and is actively encouraged by BMS, which empowers all colleagues to show up as their best authentic selves. The company’s commitment to valuing and nurturing the whole person, not just the professional, is a key reason I’ve been with BMS for so long. Additionally, my curiosity about other markets often informs my professional insights, allowing me to draw parallels and identify opportunities.

What do these opportunities look like for the future of medicine access in Ireland and beyond?
 

BMS’ vision is to transform lives through science, ensuring our innovations reach patients in need. However, medicine uptake in Ireland can often take up to two years post-approval, presenting opportunities for improvement. My goal is to work collaboratively with the government, healthcare providers, and other stakeholders to reduce this gap. The government’s recent pledge to introduce a National Life Sciences Strategy is encouraging, aiming to streamline medicine approval processes and, through increased investment in the sector, expand access to clinical trials and novel treatments for Irish patients – key priorities for me.

Delivering on this vision requires collaboration and focus. For me, it’s about advocating for equitable healthcare policies and leveraging our pipeline to meet patient needs. Success relies on three pillars: driving performance, preparing for future innovations, and empowering our people. Together, these efforts must converge on the shared goal of faster and broader patient access to transformational medicines.

What lessons can the EU adopt from the US to improve medicine access?
 

The US often outpaces the EU in medicine approval times and patient access – an area where Europe could see improvement. Streamlining regulatory processes and fostering collaboration among stakeholders could shorten access timelines. This is a focus for me. I want to advocate for policies promoting health equity and ensuring underserved patients receive timely care. Faster access to medicines remains a key area where Europe can draw inspiration from the US model.